Request Trial
jackie-7
26 November 2020Muireann Bolger

Five minutes with… Jacqueline Mulryne

Amid the unprecedented challenges presented by COVID-19, questions around the use of second medical use (SMU) patents have become increasingly pertinent. On Tuesday December 1, LSPN Connect ’s session: Addressing Second Medical Use Infringement: An Evaluation of Recent SMU Cases will examine a number of key issues relating to this pivotal area of life sciences IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026   With patent validity increasingly being fought over in both the UPC and EPO, Genevant Sciences’ Stephan Kutik talks to LSIPR about keeping parallel proceedings aligned and why teamwork matters.
Regulation & Industry
5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?
1 October 2026   LSPN Europe made its Basel debut, and two days of conversations showed just how much is changing for life sciences professionals—both in how they work and what they are being asked to do. Marisa Woutersen tallies up the talking points.
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026   The decision leaves a $177 million verdict against Lilly intact, but a dissenting judge has warned the ruling could “undermine medical innovation” by allowing overly broad patent claims to survive and provide a way around the Supreme Court’s Amgen decision.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

WATCH: Genevant IP director on tackling UPC-EPO opposition divide
5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?
Lilly loses Fed Circ rehearing bid, sparking enablement questions
Westlaw publisher scores landmark AI copyright win in US appeals court
Scientist and Chinese biotech targeted by Beam in secrets suit
Clifford Chance recruits new head of Asia-Pac
Takeda sees off UK challenge to Elvanse SPC
Conley Rose welcomes back former employee with legal and business nous